ANI Pharmaceuticals, Inc. filed a Form 8-K on November 5, 2026, announcing its financial results for the third quarter ended September 30, 2026, and providing a presentation covering those results alongside the proposed Egetis Therapeutics acquisition.

Key Highlights

  • Reporting period: Third quarter ended September 30, 2026.
  • Press release issued: ANI Pharmaceuticals issued a press release on November 5, 2026, announcing its Q3 2026 financial results, furnished as Exhibit 99.1.
  • Conference call and webcast: A call and webcast with analysts and investors was held on November 5, 2026, covering Q3 2026 results and the proposed Egetis Therapeutics acquisition.
  • Investor presentation: A presentation, attached as Exhibit 99.2, was published to the company's investor relations website in connection with the call.
  • Signing officer: The filing was signed by Stephen P. Carey, Senior Vice President Finance and Chief Financial Officer.
  • Listing: Common stock trades on the Nasdaq Stock Market under the symbol ANIP (NASDAQ:ANIP).

ANI Pharmaceuticals Discloses Q3 2026 Earnings and Egetis Acquisition Presentation

According to the filing, ANI Pharmaceuticals, Inc. reported its third-quarter 2026 financial results through a press release dated November 5, 2026, which is furnished as Exhibit 99.1. The company disclosed that this press release was issued under Item 2.02 (Results of Operations and Financial Condition) of Form 8-K. The filing notes that the information in Item 2.02 "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended," and is not automatically incorporated by reference into other filings unless specifically stated.

Under Item 7.01 (Regulation FD Disclosure), the company disclosed that it provided a presentation on November 5, 2026, in connection with a conference call and webcast held with analysts and investors. According to the filing, that presentation addressed both the company's third quarter 2026 results and "the proposed Egetis Therapeutics acquisition." The presentation is attached as Exhibit 99.2 and was also published to the investor relations section of the company's website. As with Item 2.02, the filing states that the information furnished under Item 7.01 is not deemed "filed" for Exchange Act Section 18 liability purposes.

The filing was signed on behalf of ANI Pharmaceuticals by Stephen P. Carey, identified as Senior Vice President Finance and Chief Financial Officer. ANI Pharmaceuticals is incorporated in Delaware, maintains its principal executive offices at 104 Carnegie Center Drive, Suite 300, Princeton, New Jersey 08540, and lists its common stock on the Nasdaq Stock Market under the trading symbol ANIP.

What Was Disclosed

ANI Pharmaceuticals filed a current report on November 5, 2026, furnishing its Q3 2026 earnings press release and an investor presentation covering quarterly results and the proposed Egetis Therapeutics acquisition, without detailed financial figures in the 8-K body itself.